Navigation Links
Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries
Date:8/27/2009

Stemedica Cell Technologies, Inc., a world leader in stem cell research and manufacturing (a licensed manufacturer of clinical grade biological products as licensed by the State of California Food and Drug Branch) continues to advance the stem cell industry with the presentation of two of its latest scientific discoveries at the 2009 World Stem Cell Summit.

San Diego, CA (PRWEB) Aug 27, 2009 -- Stemedica Cell Technologies, Inc., ("Stemedica"), a world leader in stem cell research and manufacturing (a licensed manufacturer of clinical grade biological products as licensed by the State of California Food and Drug Branch) continues to advance the stem cell industry with the presentation of two of its latest scientific discoveries at the 2009 World Stem Cell Summit. "We are honored to have the work of our scientific research team selected for presentation at this year's Summit. This work is expected to increase the efficacy and significantly reduce the time and cost in bringing important research from the bench top to clinical application," said Nikolai Tankovich, MD, PhD, Stemedica's President and Chief Medical Officer.

The first discovery accepted by the Summit's Peer Review Committee was submitted by Chih-Min Lin, PhD, a Stemedica Senior Research Scientist. His submittal is entitled, "Chicken Embryonic Brain: A Model for Testing Neural Stem Cell Potency". This Neural Stem Cell Evaluation Model determines the potency of neural stem cells and quickly assesses their ability to migrate and engraft inside the developing brain. Stemedica's technology allows neural precursors to be distinguished at various stages of their maturation, providing timely and cost effective verification of neural stem cell potency in vivo.

"The currently used process for assessing the in vivo potency of neural stem cells in newborn mice is extremely time consuming and expensive. This traditional process also involves the use and sacrifice of animals in facilities separate from manufacturing. Stemedica's discovery and patent pending technology eliminates the need for animals and replaces this arduous process with a significantly more effective and efficacious model. This model can be deployed within laboratory environment and the evaluation results can be attained in less than two weeks instead of the two to four months using traditional animal testing models," said Alex Kharazi, MD, PhD, Stemedica's Vice President of Research and Manufacturing.

The second finding accepted for presentation at the 2009 World Stem Cell Summit was submitted by Ludmila Kharazi, MD, PhD, Stemedica's Senior Research Scientist. Her submittal is entitled, "Up-Regulation of Wound Healing Associated Proteins in Long-Term Culture of Human Keratinocyte Precursor Cells." Dr. Kharazi's work demonstrates that long term cultivation of human keratinocytes in serum free, low-Ca++ media (SFM) leads to the increased expression of genes for wound healing-associated proteins such as fibronectin, metalloproteinase (MMP9, MMP10), and tissue-type plasminogen activator (TPA). The purpose of Dr. Kharazi's work was to determine how the propagation of human skin keratinocyte precursor cells (KPC) in SFM to clinically significant numbers will affect their ability to produce fibronectin and other wound healing associated proteins.

"Current technology for the treatment of burns, chronic wounds and diabetic ulcers is extremely expensive, time consuming and lacking in efficacy. Dr. Ludmila Kharazi's finding suggests that using long term cultivated keratinocyte precursor cells may result in reducing the time of healing while lowering the overall treatment cost. As Stemedica continues to make great advancements in products that can treat burns, chronic wounds and diabetic ulcers, Dr. Ludmila Kharazi's work is pivotal in providing the Company with advancements that will make our products, and ultimately patient treatment results, the best the industry has to offer," said Dr. Tankovich. This finding compliments Stemedica's existing proprietary burn and wound care product currently in clinical trials in Switzerland.

The 2009 World Stem Cell Summit is being held in Baltimore, Maryland from September 21st - 23rd. Presented by the Genetics Policy Institute, the 2009 Summit is hosted by Johns Hopkins University and other leadership organizations from within the stem cell industry, bringing together more than 1,200 researchers, clinicians, business leaders, key policy makers, regulators, advocates, and experts in law & ethics from around the world.

Licensing of the Stemedica's Neural Stem Cell Evaluation Model Intellectual Property is available to a select number of companies. Additionally, Stemedica is prepared to accept a limited number of projects where the Company's scientific team conducts the neural stem cell potency evaluation.

About Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies Inc. (www.stemedica.com) is a specialty biopharmaceutical company that is committed to the development and manufacturing of best-in-class adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and human clinical trials. The company is currently developing regulatory pathways for stroke and wound repair. Stemedica is headquartered in San Diego, California.

For more information regarding Stemedica Cell Technologies, Inc. contact Dave McGuigan at dmcguigan (at) stemedica.com.

Read the full story at http://www.prweb.com/releases/Stemedica-research/world-stem-cell-summit/prweb2793034.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
2. CIRM Completes Briefing Visit to Stemedica Cell Technologies
3. Renowned Stem Cell Researcher Files Study Results With Stemedica
4. Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher
5. Stemedica Requests Pre-IND Meeting With FDA
6. Biomaxx Systems Inc. Selected as Technical Consultant By Southern Cross Agricultural Developments
7. Solazyme, Inc. Selected by AlwaysOn as a GoingGreen 100 Top Private Company Award Winner
8. Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project
9. AG Mednet Selected By Massachusetts General Hospital to Transport 3D Post-Processing Images
10. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
11. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries
(Date:12/9/2016)... /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the Company") ... announce that Biohaven has issued today the following press ... (PRWEB) Dec 9, 2016 - Biohaven Pharmaceutical Holding ... the U.S. Food and Drug Administration ("FDA") has granted ... candidate BHV-0223, an orally dissolving tablet being developed for ...
(Date:12/8/2016)... CA (PRWEB) , ... December 08, 2016 , ... Lajollacooks4u, ... was a banner year for team building events, new program offerings and company expansion. ... it expanded earlier this year to include groups of over 30 people. Ever since, ...
(Date:12/8/2016)...  Biotheranostics today announced that new data will ... Cancer Index (BCI) in identifying which patients with ... for disease recurrence and might benefit from extended ... advancing the understanding of the value of BCI ... inform decisions related to patient treatment. These data ...
(Date:12/8/2016)... ... December 08, 2016 , ... Opal Kelly, ... essential device-to-computer interconnect using USB or PCI Express, announced the FOMD-ACV-A4, the company's ... is a small, thin, SODIMM-style module that fits a standard 204-pin SODIMM socket ...
Breaking Biology Technology:
(Date:11/29/2016)... , November 29, 2016 Nearly one billion ... Continue Reading ... ... part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The ...
(Date:11/21/2016)... Lithuania , Nov. 21, 2016   ... and object recognition technologies, today announced that the ... smart cards was submitted for the NIST ... successfully passed all the mandatory steps of the ... evaluation is a continuing test of fingerprint templates ...
(Date:11/15/2016)... Nov. 15, 2016  Synthetic Biologics, Inc. (NYSE ... focused on the gut microbiome, today announced the ... shares of its common stock and warrants to ... a price to the public of $1.00 per ... Biologics from the offering, excluding the proceeds, if ...
Breaking Biology News(10 mins):